Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer
NCT02760030Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2017
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, fulvestrant in breast cancer, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Feb 2017; status: completed.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02760030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760030.